Nuveen Asset Management LLC Purchases 34,660 Shares of Sanofi (NASDAQ:SNY)

Nuveen Asset Management LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,676,224 shares of the company's stock after acquiring an additional 34,660 shares during the quarter. Nuveen Asset Management LLC owned about 0.14% of Sanofi worth $177,304,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new position in Sanofi in the 4th quarter valued at about $25,000. McClarren Financial Advisors Inc. increased its holdings in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new stake in shares of Sanofi during the fourth quarter worth approximately $31,000. Bessemer Group Inc. lifted its holdings in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares during the period. Finally, Sierra Ocean LLC purchased a new position in Sanofi in the 4th quarter valued at $44,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNY has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. BNP Paribas initiated coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $63.33.

Sanofi Price Performance

Shares of Sanofi stock traded up $0.60 on Monday, hitting $52.28. The company had a trading volume of 1,500,928 shares, compared to its average volume of 2,377,379. The company has a market cap of $132.07 billion, a PE ratio of 21.00, a PEG ratio of 1.01 and a beta of 0.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The business has a 50-day simple moving average of $53.36 and a 200-day simple moving average of $51.88.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business's revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.78 EPS. Research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a $2.0369 dividend. The ex-dividend date of this dividend is Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio is 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.